| WestRock [WRK] - Last Close: $31.88 Merger rumors are lifting shares of WestRock today. This morning, the company confirmed it is currently negotiating a potential merger agreement with Smurfit Kappa Group. WestRock says it's pursuing a merger to create a new sustainable packaging holding company, and both companies are currently discussing key terms. If they reach an agreement, the new company would be called Smurfit WestRock, and it could have cost synergies exceeding $400 million in just its first year. WRK is leading the S&P 500 with a 6.6% gain today. My Take: WRK is holding onto a nice up-trend on its chart, and a merger could be a big catalyst to send shares higher. This could be worth watching. CymaBay Therapeutics [CBAY] - Last Close: $13.83 Upbeat drug data is boosting shares of CymbaBay. The biotech announced a Phase 3 RESPONSE trial of seladelpar met its primary and secondary endpoints in biliary cholangitis patients. CymaBay said the trial results support the drug's advancement to regulatory approval filings with the FDA, MHRA, and EMA. The trial found that 61.7% of patients on the drug met the primary composite endpoint with a safety profil similar to placebo. CBAY is one of this morning's top stocks with a 23.0% gain on active premarket trading volume. My Take: It sounds like CBAY is on the verge of an all-out approval for seladelpar. After this trial, most of the good news is probably priced into the stock, but an approval could deliver another catalyst in the coming weeks. Wheeler REIT [WHLR] - Last Close: $4.54 Wheeler REIT is exploding after an announcement. On Tuesday, the real estate investment trust regained compliance with Nasdaq's minimum bid price requirement listing rule. Nasdaq opened a non-compliance complaint against the company in June, but the matter is officially closed as of yesterday. WHLR has been running hot since the Nasdaq ruling. Shares jumped 6.9% on Wednesday, but they really took off in today's premarket. WHLR is one of this morning's top-performing stocks with a 109.6% gain on active trading volume. My Take: I'm not sure why this stock is experiencing such a dramatic move today, but, boy, I wish I got in on this rally. This is a nice niche-focused REIT that could be worth owning. Asensus Surgical [ASXC] - Last Close: $0.29 Asensus Surgical has a powerful new partner. This morning, the company announced a partnership with NVIDIA [NVDA] to drive the development and improvement of its Intelligent Surgical Unit. Under the terms of the deal, Asensus will utilize a broad suite of NVIDIA tools to enhance the augmented intelligence capabilities of its ISU. Asensus and NVIDIA also plan to jointly explore innovative business models for the development, deployment, and commercialization of digital surgical solutions. ASXC is breaking out on the news. It's currently up 34.0% on active trading volume. My Take: ASXC's tech was impressive enough to get NVDA on board, but is it really a quality company, or is this just another buzzword rally? It's hard to tell at this point, but NVIDIA's partnership definitely lends Asensus some credibility. GainersAmerican Rebel [AREB] >> +39.6%China SXT Pharma [SXTC] >> +27.5%Rosecliff Acquisition [RCLF] >> +22.4%MariaDB [MRDB] >> +19.8%DeclinersNeuBase Therapeutics [NBSE] >> (24.3%) Sportsman Warehouse [SPWH] >> (23.3%)Verint Systems [VRNT] >> (17.2%)Palisade Bio [PALI] >> (20.1%) The Toro Company [TTC] ... AM
Science Applications International Corporation [SAIC] ... AM
Abm Industries Incorporated [ABM] ... AM
Korn Ferry [KFY] ... AM
John Wiley & Sons, Inc. [WLY] ... AM
Docusign, Inc. [DOCU] ... PM
RH [RH] ... PM
Guidewire Software, Inc. [GWRE] ... PM
Smartsheet Inc. [SMAR] ... PM
Braze, Inc. [BRZE] ... PM Initial jobless claims [Sep] ... 8:30a U.S. productivity (revision) [Q2] ... 8:30a Unit-labor costs (revision) [Q2] ... 8:30a |
